Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Hidradenitis Suppurativa,Psoriasis,Crohn Disease,Uveitis,Arthritis, Rheumatoid,Arthritis,Colitis, Ulcerative,Spondylitis, Ankylosing,Arthritis, Psoriatic, Date of authorisation: 24/08/2017, Revision: 10, Status: Authorised
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.